Melbourne, June 20, 2026, 02:04 AEST
- CSL jumped 7.62% to finish at A$116.32 on Friday, logging its best session in over four years.
- The stock climbed 8.2% this week. The ASX healthcare index put on about 5%.
- CSL is set to release its full-year results and announce its final dividend on August 18.
CSL Ltd rallied hard Friday, gaining 7.6% to A$116.32 and closing at its high for the day, even as the S&P/ASX 200 slid 0.92% to 8,828.7. The stock, long out of favor with sellers, moved higher while most of the market fell.
With the exchange shut for the weekend, the question is set for Monday. Did this rally in CSL stick, or was it just a quick bounce as positions shifted? CSL gave no new operating details with the move. Its investor page lists the latest ASX release from June 9. The simple read is the price moved before the business story did.
Defensive rotation showed up in the market, with traders buying up stocks seen as safer from big shifts in economic growth. This followed months of heavy losses in healthcare. Michael McCarthy, market strategist at Moomoo, said overall volume was weak, calling it “not a panic, but rather a buyers’ strike.” Money moved between sectors but stopped short of flowing into Australian equities as a whole. Morningstar
CSL traded over 8 million shares on Friday, with turnover much higher than earlier in the week. Still, the stock closed about 58% under its 52-week high of A$275.79, and sits 29% above its A$90 low. The move shows a sharp bounce from deep losses, but CSL hasn’t regained its old valuation.
Morningstar equity strategist Lochlan Halloway called shares “undervalued”, taking a more upbeat view on plasma demand and margins than most of the market. Halloway puts long-term immunoglobulin revenue growth at about 5%. Immunoglobulins are antibody medicines from donated plasma. He does see price competition eating into CSL’s cost savings and points to Roche’s haemophilia drug Hemlibra as a threat. Morningstar
CSL last gave a detailed financial update on May 11, when it cut its constant-currency revenue outlook for fiscal 2026 to about US$15.2 billion. It also lowered its NPATA forecast to around US$3.1 billion, not counting restructuring and impairment charges. NPATA stands for net profit after tax before amortisation on IP and big one-offs. CSL also told markets to expect about US$5 billion more in non-cash, pre-tax write-downs by the end of fiscal 2027.
CSL’s downgrade factors in a US$300 million hit from cutting excess U.S. immunoglobulin stock, US$200 million in lower albumin values in China, plus US$150 million after disruptions in the Middle East, slow Hemgenix sales and rivals in iron drugs. Interim CEO Gordon Naylor said CSL “had not executed as well as it should have.” He said that matters more for the company’s long-term story than just the day’s trading. ABC News
But risks are still out there. A rally built on flows can unwind if the forced buying slows. Another round of earnings cuts, slower cost drops from plasma collection, or a fresh drop in U.S. vaccine demand could shake confidence again. CSL held off splitting off its Seqirus vaccine unit after U.S. vaccination rates fell, so the operational and structural questions are still open.
S&P/ASX 200’s quarterly reshuffle kicks in before the bell Monday. Five names out, five in, with CSL staying put. Now, the focus turns to whether regular buyers will step up after the forced trades run their course. The index needs to see real improvement in execution to hold higher ground. Friday’s action gave a boost, but didn’t offer proof.
